Truist Financial’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Truist Financial’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,238	Closed	-$240K	–	2707
2023 Q1	$240K	Sell	2,238 -1,711	-43%	-$197K	﹤0.01%	2336
2022 Q4	$434K	Buy	3,949 +424	+12%	+$27.5K	﹤0.01%	2062
2022 Q3	$208K	Buy	+3,525	New	+$161K	﹤0.01%	2289

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Truist Financial's RXDX Position: Q2 2023 in Review

Truist Financial sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,238 shares — an estimated $240K sold.

Truist Financial first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $434K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Truist Financial reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Truist Financial sold 2,238 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $240K.
Truist Financial first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Truist Financial's Prometheus Biosciences, Inc. Common Stock position peaked at $434K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Truist Financial's 13F filing for Q2 2023, filed 1 Aug 2023.